IL-17A, IL-17F, and IL-22 display anti-tumor effects in CRC, aiding immune cell recruitment, tissue repair, and reducing inflammation and angiogenesis-promoting factors (36). This evidence concerns the gene IL22 and colorectal carcinoma.